AIM:To examine the association between statin use and the development of esophageal cancer METHODS:We performed a systematic review and meta-analysis.Multiple databases(Pubmed,EMBASE,Cochrane Library,Web of Science,Wiley Interscience and Google Scholar) were systematically searched for studies reporting the association of statin use and the development of esophageal cancer.Literature searching and data abstraction were performed independently by two separate researchers.The quality of studies reviewed was evaluated using the Newcastle-Ottawa Quality assessment scale.Meta-analysis on the relationship between statin use and cancer incidence was performed.The effect of the combination of statin plus a cyclo-oxygenase inhibitor was also examined.RESULTS:Eleven studies met eligibility criteria,9 high and 2 medium quality.All were observational studies.Studies examining adenocarcinoma development in Barrett’s esophagus included 317 cancers and 1999 controls,population-based studies examining all esophageal cancers included 371203 cancers and 6083150 controls.In the Barrett’s population the use of statins(OR = 0.57;95%CI:0.43-0.75) and cyclo-oxygenase inhibitors(OR = 0.59;95%CI:0.45-0.77) were independently associated with a reduced incidence of adenocarcinoma.Combined use of a statin plus cyclooxygenase inhibitor was associated with an even lower adenocarcinoma incidence(OR = 0.26;95%CI:0.1-0.68).There was more heterogeneity in the population-based studies but pooled adjusted data showed that statin use was associated with a lower incidence of all combined esophageal cancers(OR = 0.81;95%CI:0.75-0.88).CONCLUSION:Statin use in patients with Barrett’s oesophagus is associated with a significantly lower incidence of adenocarcinoma.The chemopreventive actions of statins,especially combined with cyclooxygenase inhibitors deserve further exploration. AIM: To examine the association between statin use and the development of esophageal cancer METHODS: We performed a systematic review and meta-analysis. Multiple databases (Pubmed, EMBASE, Cochrane Library, Web of Science, Wiley Interscience and Google Scholar) were systematically searched for studies reporting the association of statin use and the development of esophageal cancer. Lateral searching and data abstraction were performed separately by two separate researchers. The quality of the study reviewed was evaluated as the Newcastle-Ottawa Quality Assessment Scale. Meta-analysis on the relationship between statin use and cancer incidence was performed. The effect of the combination of statin plus a cyclo-oxygenase inhibitor was also examined .RESULTS: Eleven studies eligibility criteria, 9 high and 2 medium quality. All were observational studies. Judies examining adenocarcinoma development in Barrett’s esophagus included 317 cancers and 1999 controls, population-based studies examining All esophageal cancers included 371203 cancers and 6083150 controls.In the Barrett’s population the use of statins (OR = 0.57; 95% CI: 0.43-0.75) and cyclo-oxygenase inhibitors (OR = 0.59; 95% CI: 0.45-0.77) were independently associated with a reduced incidence of adenocarcinoma. Combined use of a statin plus cyclooxygenase inhibitor was associated with an even lower adenocarcinoma incidence (OR = 0.26; 95% CI: 0.1-0.68). There was more heterogeneity in the population-based studies but pooled adjusted data showed that statin use was associated with a lower incidence of all combined esophageal cancers (OR = 0.81; 95% CI: 0.75-0.88) .CONCLUSION: Statin use in patients with Barrett’s oesophagus is associated with a significantly lower incidence of adenocarcinoma The chemopreventive actions of statins, especially combined with cyclooxygenase inhibitors deserve further exploration.